News | October 27, 2014

Miracor Begins European Launch of New PICSO Impulse System

System designed to reduce severe heart attack impairment as an adjunct therapy with angioplasty in acute STEMI and NSTEMI patients

October 27, 2014 — Miracor Medical Systems announced today the successful launch of its next-generation Pressure-Controlled Intermittent Coronary Sinus Occlusion (PICSO) Impulse System for the treatment of myocardial infarction. The new PICSO Impulse System, consisting of the Impulse Console and Impulse Balloon Catheters, is CE-marked and has already been used to treat patients in the U.K., Ireland and Hungary.

PICSO is designed to increase myocardial perfusion in conjunction with primary percutaneous coronary intervention (PCI) or angioplasty and thereby reduce infarct size and improve cardiac function. To date nearly 160 patients have been treated, and the most recent clinical trial data presented at EuroPCR 2014 confirmed the significant impact of the Miracor PICSO technology on infarct size-reduction in patients who had received PICSO therapy following PCI compared to a control group. Additionally the data confirmed the safety profile of the PICSO technology.

A new, smaller balloon catheter now addresses variable patient anatomies as well as physician preferences and provides improved handling and increased balloon stability during PICSO therapy.

“I was able to place the balloon very easily in the coronary sinus and immediately achieved a stable position,“ said Prof. Béla Merkely, M.D., chairman and director at the Semmelweis University Heart and Vascular Center in Budapest, Hungary, after using the new PICSO therapy in a ST-segment elevation myocardial infarction (STEMI) and a non-STEMI patient.

“The system provided continuous and stable therapy during my coronary intervention, and I look forward now to see the long-term benefits for our patients with myocardial infarction,” added Levente Molnár, M.D., from the Semmelweis University Heart and Vascular Center.

The PICSO Impulse System’s console and software also have been updated to facilitate faster, safe and effective therapy delivery. Piers Clifford, M.D., cardiology consultant and clinical lead for cardiology, Buckinghamshire Healthcare NHS, who used the new PICSO Impulse System at the Wycombe Hospital in High Wycombe, Buckinghamshire, U.K., commented: “I’m very pleased to see the advancements that have been made to the PICSO system, which now make it even easier and faster to use without interrupting our workflows. I’m convinced that the PICSO Impulse System will change the way we treat patients with ST-segment elevation and non-ST-segment elevation myocardial infarction.”

For more information: www.miracormedical.com

Related Content

Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology cath lab Market.
Feature | Cath Lab | May 07, 2018 | Simon Trinh and Jeffrey Wong
The European interventional cardiology market is currently valued at nearly $1.4 billion.
Videos | Cath Lab | May 07, 2018
Imran Ahmad, M.D., medical director of interventional cardiology, explains some of the new technologies his labs have
360 Photos | Cath Lab | April 20, 2018
A 360 degree view of the newest cath lab at Northwestern Medicine Central DuPage Hospital in Winfield, Ill., located
SCAI Announces Global Lecture Series for 2018 Scientific Sessions
News | Cath Lab | April 18, 2018
Many of the world’s leading interventional cardiologists and cardiovascular professionals will convene in San Diego,...
Overlay Init